Table 4.

Risk of malignancy with ThyroSeq mutations (resected nodules) by institution MSKCC, Memorial Sloan-Kettering Cancer Center; MCC, Moffitt Cancer Center; CSMC, Cedars-Sinai Medical Center; MSHS, Mount Sinai Health System. NIFTP was considered benign to calculate the rates of malignancy.

	MSKCC	MCC	CSMC	MSHS	Institutions Combined
ALK TD Domain overexpression		0% (0/1)			0% (0/1)
BRAF V600E		100% (2/2)		100% (3/3)	100% (5/5)
BRAF K601E	0% (0/1)	50% (1/2)		0% (0/1)	25% (1/4)
BRAF L597V		100% (1/1)			100% (1/1)
BRAF deletion	0% (0/1)				0% (0/1)
BRAF K601E & EIF1AX	0% (0/1)				0% (0/1)
EIF1AX	67% (2/3)	0% (0/3)		0% (0/2)	25% (2/8)
EIF1AX + TSHR		0% (0/1)			0% (0/1)
ETV6/NTRK3				100% (1/1)	100% (1/1)
MET Overexpression	0% (0/2)	50% (1/2)	100% (1/1)	0% (0/2)	29% (2/7)
NTRK3	100% (3/3)				100% (3/3)
PAX8/PPARG	50% (3/6)	100% (1/1)	0% (0/1)	33% (1/3)	45% (5/11)
HRAS Q61 (K,R)	13% (1/8)	50% (1/2)	0% (0/2)	0% (0/2)	14% (2/14)
KRAS Q61 (K, R), G12V, G12D	40% (2/5)	0% (0/3)	50% (1/2)	33% (1/3)	31% (4/13)
NRAS Q61 (K, R), G13R	43% (12/28)	20% (2/10)	0% (0/4)	7% (1/15)	26% (15/57)
Isolated RAS mutations	37% (15/41)	20% (3/15)	13% (1/8)	10% (2/20)	25% (21/84)
HRAS & Calcitonin expression	100% (1/1)				100% (1/1)
HRAS & EIF1AX	100% (1/1)			0% (0/2)	33% (1/3)
KRAS & EIF1AX	0% (0/1)				0% (0/1)
NRAS & EIF1AX	67% (2/3)				67% (2/3)
NRAS & TERT promoter	0% (0/1)		100% (1/1)		50% (1/2)
NRAS & TERT promoter & EIF1AX	100% (1/1)	100% (1/1)			100% (2/2)
All RAS mutations	41% (20/49)	25% (4/16)	22% (2/9)	9% (2/22)	29% (28/96)
RET/PTC1	100% (1/1)			100% (1/1)	100% (2/2)
TERT promoter	0% (0/1)				0% (0/1)
THADA/IGF2BP3	50% (2/4)	33% (1/3)		0% (0/1)	38% (3/8)
TP53	100% (1/1)			0% (0/1)	50% (1/2)
TSHR	0% (0/1)	0% (0/1)			0% (0/2)
Mutations Combined	43% (32/74)	33% (11/33)	27% (3/11)	22% (8/37)	35% (54/155)